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Abstract
Background:  Many kidney transplant recipients have hypertension. Elevated systolic blood
pressures are associated with lower patient and kidney allograft survival.
Methods: This retrospective analysis examined the prevalence of clinical inertia (failure to initiate
or increase therapy) in the treatment of hypertension before and after the introduction of an
automated device (BpTRU) in the kidney transplant clinic.
Results: Historically only 36% (49/134) of patients were prescribed a change in therapy despite a
systolic blood pressure ≥ 130 mmHg. After the introduction of BpTRU, 56% (62/110) of the
patients had a change in therapy. In a multivariate logistic regression analysis of the entire cohort
(n = 244) therapeutic changes were associated with higher blood pressures (OR 1.08 per mmHg,
95% CI 1.04–1.12) and use of the BpTRU (OR 2.12, 95% CI 1.72–3.83). In addition patients on more
medications were also more likely to have a change in therapy.
Conclusion:  Blood pressure measurement with automated devices may help reduce clinical
inertia in the kidney transplant clinic.
Background
Several studies have shown that higher blood pressures
are associated with reduced kidney allograft and patient
survival [1-3]. For every 10 mmHg higher systolic pressure
graft loss is increased by 12–15% [2,3]. The guidelines rec-
ommend blood pressure targets of <130/85 mmHg [4].
Despite these guidelines many patients have blood pres-
sures above this level [1,3].
Blood pressure is difficult to control in kidney transplant
recipients in part because of the associated immunosup-
pressive medication, impaired graft function, older age,
obesity and diabetes mellitus [3]. Many studies however
report that clinicians under treat patients [5-7]. The litera-
ture describes the phenomena of clinical inertia when
physicians fail to initiate or intensify therapy when war-
ranted [6,7]. There is a growing literature on clinical iner-
tia and hypertension in the general population but less is
known in the kidney transplant population.
In a recent American Heart Association scientific state-
ment, the authors point out the shortcomings of ausculta-
tory office blood pressures in the clinical practice despite
their long standing importance in clinical research [8].
Patients commonly report that their blood pressures are
better at home and are aware of the white coat phenom-
ena. Many clinics are not performing research quality
blood pressure measurements. For these reasons clini-
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cians may doubt the precision or certainty of the measure-
ment and a therapeutic change will be deferred.
Ambulatory blood pressure monitoring devices are one
strategy to increase diagnostic accuracy and may better
predict outcomes [8]. Unfortunately 24 hour ambulatory
blood pressure monitoring is not convenient, especially
for patients traveling great distances. One automated
device that meets hypertension standards and that can be
used in the office is the BpTRU automated device [9,10].
The mean difference between the reference standard systo-
lic and BpTRU systolic measurement in one study was
0.47 ± 5.4 mmHg with 89.2 % of the measurements
within 5 mmHg [10]. The BpTRU was also a better esti-
mate of ambulatory blood pressures than routine office
measurements [11] We introduced the BpTRU device in
our clinic on the recommendation of our hospital hyper-
tension experts. In this report we describe our experience
with the device and explore the impact on therapeutic
changes in hypertensive kidney transplant recipients.
Methods
In October 2005, the clinic introduced the BpTRU device
(VSM Medtech Ltd, Coquitlam, British Columbia, Can-
ada). This device employs the oscillometric technique
used by most home and ambulatory blood pressure
devices. It reads 6 blood pressure measurements every 2
minutes while the patient is seated quietly alone in a
room. The first measurement is ignored and the last 5
measurements are averaged.
In November the clinic prospectively used the device on
patients with a blood pressure ≥ 130 mmHg systolic by
the clinic's aneroid syhygmomanometer. Both blood pres-
sure values were recorded. To test the hypothesis that the
device had an impact on initiating or intensifying therapy,
these patients (BpTRU group) were retrospectively
reviewed. The comparators were historic patients (Control
group) with a systolic blood pressure ≥ 130 mm Hg who
had been in clinic within the year prior to the introduc-
tion of the BpTRU. Inclusion into both cohorts was based
on the clinic's aneroid syhygmomanometer blood pres-
sure. This was a retrospective analysis and individual
informed consent was not obtained. Permission to per-
form the study was provided by our institution research
ethics committee.
All patients were adults (>18) and were either kidney
alone or combined kidney pancreas transplant recipients.
Patients transplanted within 6 months were excluded. For
patients who had several BpTRU measurements only the
first was analyzed. Data on patient age, weight, height,
sex, serum creatinine, glomerular filtration rate, diabetes
mellitus status, resistant hypertension, attending physi-
cian, antihypertensive and immunosuppression medica-
tion use were collected. Glomerular filtration rate was
estimated by the MDRD 4 variable equation [12]. Resist-
ant hypertension was defined as receiving 3 or more
blood pressure lowering medications with one being a
diuretic [13]. The outcome measure was a change in ther-
apy. For the purpose of this study newly added antihyper-
tensive therapy, increase in the dose of current
antihypertensive therapy, and reductions in calcineurin
inhibitor or prednisone doses were consider therapeutic
changes. Our clinic's written policy is that blood pressure
be controlled to <130/85 mmHg [4]. Patients had already
been given dietary advice to achieve and maintain ideal
body weight and limit salt intake. No other specific poli-
cies or procedures were introduced over the study time
period.
A statistically significant increase in therapy with the
introduction of BpTRU was tested by Chi-square analysis.
Differences between group (Control versus BpTRU)
demographics were tested by Chi-square for dichotomous
variables and ANOVA for continuous variables. A level of
significance was set at 5%. A multivariate logistic regres-
sion analysis was performed on the entire cohort (n =
244) to look at independent predictors of a therapeutic
change.
Results
Table 1 shows the patient demographics and clinical
descriptors of the two groups. There were slightly more
patients with diabetes mellitus in the control population
whereas diastolic blood pressure was higher in the BpTRU
sample. There were no statistical differences between indi-
vidual antihypertensive medications such as calcium
channel blockers, beta blockers, angiotensin enzyme
inhibitors, angiotensin receptor blockers, diuretics or
other blood pressure medication. Calcineurin inhibitor
and prednisone use were similar.
There were more changes in therapy (p = 0.002) in the
BpTRU group (56%) compared to historic controls (36%)
(Table 1). Changes in therapy included new antihyperten-
sive medication (n = 18), increase in antihypertensive
medication dose (n = 22) and lowered immunosuppres-
sion (n = 9) in the control group. The medications added
included ACEI/ARB (n = 9), diuretic (n = 3), calcium
channel blocker (n = 3) beta-blocker (n = 2), and alpha-
blocker (n = 1). For the BpTRU group changes in therapy
included new antihypertensive medication (n = 25),
increase in antihypertensive medication dose (n = 23) and
lowered immunosuppression (n = 14). The medications
added included ACE/ARB (n = 13), diuretic (n = 8), cal-
cium channel blocker (n = 1) and beta-blocker (n = 3).
The types of changes made were not statistically different.
Analysis of the entire cohort by logistic regression analysis
(Table 2) found that level of systolic blood pressure,BMC Nephrology 2007, 8:10 http://www.biomedcentral.com/1471-2369/8/10
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number of antihypertensive medications the patient was
already on, and use of the BpTRU device were associated
with more changes in therapy. Other variables such as age,
weight, GFR, BMI, attending physician, kidney function,
individual antihypertensive or immunosuppressive medi-
cation use were not significant predictors.
Within the BpTRU group not all patients were hyperten-
sive by the automated device. Only 72 of the 110 patients
(66%) had a blood pressure that was ≥ 130 mmHg systo-
lic with the BpTRU. Therapeutic changes were made in 49
of the 72 (68%). In those with BpTRU <130 mmHg systo-
lic therapeutic changes were made in 13 of the 38 (38%)
patients.
Discussion
The results show that more significantly therapeutic
changes were made in hypertensive kidney transplant
recipients being followed in the clinic during the period of
BpTRU use. The device may have provided some measure-
ment certainty to both patient and physician to the extent
that more changes were made. The two other factors asso-
ciated with therapeutic changes also provide measures of
certainty. Patients on more medications may be perceived
by the clinician as more likely to have uncontrolled blood
pressure. Similarly patients with higher blood pressures
are more likely to have truly elevated pressures.
Clinical inertia in the treatment of hypertension is not a
new phenomenon but has not been reported in the kid-
ney transplant literature. In a recent study of outpatient
general population practices in the southeastern United
States, 7253 hypertensive patients were evaluated [5].
Changes in therapy occurred in only 13.1% of clinic visits
in patients with blood pressures exceeding >140/90
mmHg. The authors estimated that increasing medication
doses in 30% of patients would have increased the
number of patients in target from 45.1% to 65.9%. In our
historic group of kidney transplant recipients changes
were made in 36% of patients. Although this might
appear to be significantly better, therapeutic changes were
made in 49% of hypertensive kidney disease patients
attending Canadian general nephrology clinics [14].
Although differences in the study populations preclude
detailed comparisons, therapeutic changes are occurring
in a <50% of patients even under specialist care. If antihy-
pertensive therapy is not intensified in the kidney trans-
plant population it should be no surprise that most will
have blood pressures exceeding target levels [1,3].
There are several limitations of the study. This study was
not randomized, nor blinded. We also cannot say that
other secular influences might have also been associated
with changes in prescribing patterns. We used historic
rather than concurrent controls. Follow up blood pres-
sures were not obtained. However, more than two thirds
of patients in both groups did not meet the criteria for
hypertension resistance, suggesting more intense therapy
should be helpful. Our clinic blood pressures were best
described as casual. Our clinic does not ensure the
research standard for a clinical trail (no caffeine or nico-
Table 2: Associations with therapeutic changes: multivariate logistic regression analysis
EXP(B) 95% CI probability
BP systolic (per mm Hg) 1.079 1.041–1.119 <0.001
BpTRU (yes) 2.118 1.717–3.833 0.013
AHM total (per med) 1.417 1.085–1.851 0.011
AHM -antihypertensive medication
Adjusted for patient age, sex, BMI, physician, and diabetes mellitus status
Table 1: Demographic and clinical descriptors
Control N = 
134
BpTRU N = 110 prob
Age (years) 52 ± 13 53 ± 13
Sex (male) 83 (62) 66 (60)
Diabetes mellitus (%) 54 (40) 30 (27) 0.042
ESRD n (%)
Diabetes mellitus 27 (20) 20 (18)
Glomerulonephritis 23 (17) 22 (20)
Polycystic kidney disease 46 (34) 36 (33)
Hypertension 16 (12) 14 (13)
Interstitial nephritis 13 (10) 12 (11)
Other 9 (7) 6 (5)
Duration of transplant (yrs) 7.7 ± 6.1 7.2 ± 6.1
Body weight (kg) 85.5 ± 19.1 83.1 ± 19.2
BMI (kg/m2) 30.1 ± 6.7 28.9 ± 6.1
Creatinine (µmol/L) 141 ± 52 152 ± 72
GFR ml/min/1.73 m2 65.9 ± 26.0 61.3 ± 28.3
BP systolic (mm Hg) 143 ± 10 145 ± 7 0.082
BP diastolic (mm Hg) 81 ± 10 85 ± 11 0.002
BpTRU systolic NA 136 ± 18
BpTRU diastolic NA 83 ± 13
Change made (%) 49 (36) 62 (56) 0.002
CNI (yes) (%) 124 (93) 99 (90)
Prednisone (yes) (%) 102 (76) 87 (79)
AHM total meds 2. 2 ± 1.1 2.2 ± 1.2
Resistant HTN 39 (29%) 35 (32%)
BMI- Body mass index (kg/m2)
GFR- glomerular filtration rate (MDRD formula)
CNI- calcineurin inhibitor
AHM- antihypertensive medication
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tine 20 minutes before, seated with back supported for 5
minutes, not engaged in conversation, two measurements
a few minutes apart, agreement within 5 mm Hg, avoid
terminal digit preference) [15]. Clinics that ensure this
level of quality probably do not require this type of assist-
ance to improve blood pressure certainty. We analysed
systolic blood pressure as the primary variable rather than
diastolic as this most closely correlates with outcome [1-
3] Ambulatory blood pressures would be preferred and
are carried out at our center, but geographical issues and
availability limit this method in many of our patients. We
unfortunately did not collect data on patient home mon-
itoring. In addition, the device has no terminal digit pref-
erence and can be used efficiently in busy clinics.
Conclusion
Although there are no randomized control trials in the
kidney transplant population there is a wealth of cohort
data and considerable evidence in the general population
supporting blood pressure control to preserve kidney
function and reduce mortality. It is not clear from this
small single center retrospective review whether an auto-
mated device or other strategies to increase measurement
certainty will reduce clinical inertia over the long run and
improve overall patient outcomes. This degree of evidence
would require a large randomized trial. Nonetheless we
hope this study encourages others to scrutinize their prac-
tice and consider the necessary steps to ensure that blood
pressure targets are achieved with the ultimate goal of
increasing patient and allograft survival.
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